GUTS
Fractyl Health, Inc. Common Stock
NASDAQ: GUTS · HEALTHCARE · BIOTECHNOLOGY
$0.64
+5.90% today
Updated 2026-04-30
Market cap
$103.61M
P/E ratio
—
P/S ratio
7,575.74x
EPS (TTM)
$-1.86
Dividend yield
—
52W range
$0 – $3
Volume
2.3M
Fractyl Health, Inc. Common Stock (GUTS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $120000.00 | $93000.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | -22.5% | -100.0% |
| Cost of revenue | $893000.00 | $770000.00 | $676000.00 | $452000.00 | $77000.00 | $50000.00 | $1.13M |
| Gross profit | $-893000.00 | $-770000.00 | $-676000.00 | $-452000.00 | $43000.00 | $43000.00 | $-1.13M |
| Gross margin | — | — | — | — | 35.8% | 46.2% | — |
| R&D | $20.89M | $22.43M | $26.43M | $34.35M | $38.04M | $70.47M | $74.54M |
| SG&A | $9.03M | $6.53M | $10.49M | $15.03M | $12.84M | $23.10M | $22.28M |
| Operating income | $-29.92M | $-28.96M | $-36.93M | $-49.38M | $-50.84M | $-93.53M | $-96.82M |
| Operating margin | — | — | — | — | -42363.3% | -100571.0% | — |
| EBITDA | $-29.03M | $-28.19M | $-36.25M | $-48.93M | $-50.55M | $-92.85M | $-95.69M |
| EBITDA margin | — | — | — | — | -42125.0% | -99843.0% | — |
| EBIT | $-29.92M | $-28.96M | $-36.93M | $-49.38M | $-50.84M | $-93.53M | $-96.82M |
| Interest expense | $635000.00 | $1.50M | $1.44M | — | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-30.59M | $-30.48M | $-38.73M | $-46.45M | $-77.09M | $-68.69M | $-140.95M |
| Net income growth (YoY) | — | +0.4% | -27.1% | -19.9% | -66.0% | +10.9% | -105.2% |
| Profit margin | — | — | — | — | -64242.5% | -73864.5% | — |